News

Lynparza has been designed to exploit DNA damage response (DDR) pathway deficiencies, like the BRCA mutations, to preferentially eliminate cancer cells. Especially, in vitro studies have demonstrated that

The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing. The Garnet Valley site will focus on developing small molecule

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific

PCI provides a full service Returns Management service for our clients, providing visibility and accountability in returning investigational drug product from investigational sites at the conclusion of a

The study has achieved the primary endpoint by demonstrating Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an

Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had granted Orphan Drug Designation to BPS-804 for osteogenesis imperfecta, a rare, chronic genetic

aGvHD is a leading cause of death following an allogeneic stem cell transplant due to the transplanted immune cells attacking the patient’s tissues. It results in a very

This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and

As part of the deal, Adynxx stockholders will become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis. The public clinical-stage pharmaceutical firm will involve